Industry Strength Score
11/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NEVRO CORP (NVRO) Stock Price & Overview
NYSE:NVRO • US64157F1030
Current stock price
5.84 USD
0 (0%)
At close:
5.8401 USD
0 (0%)
After Hours:
The current stock price of NVRO is 5.84 USD. Today NVRO is down by 0%. In the past month the price increased by 0.86%. In the past year, price decreased by -56.06%.
NVRO Key Statistics
52-Week Range3.165 - 13.84
Current NVRO stock price positioned within its 52-week range.
1-Month Range5.73 - 5.86
Current NVRO stock price positioned within its 1-month range.
- Market Cap
- 221.219M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.92
- Dividend Yield
- N/A
NVRO Stock Performance
Today
0%
1 Week
-0.17%
1 Month
+0.86%
3 Months
+57.41%
Longer-term
6 Months +17.51%
1 Year -56.06%
2 Years -80.05%
3 Years -90.53%
5 Years -95.04%
10 Years -87.03%
NVRO Stock Chart
NVRO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NVRO. When comparing the yearly performance of all stocks, NVRO is one of the better performing stocks in the market, outperforming 72.33% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NVRO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVRO. Both the profitability and financial health of NVRO have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NVRO Earnings
On March 4, 2025 NVRO reported an EPS of -0.4 and a revenue of 105.55M. The company beat EPS expectations (49.33% surprise) and beat revenue expectations (0.92% surprise).
Next Earnings DateMay 5, 2025
Last Earnings DateMar 4, 2025
PeriodQ4 / 2024
EPS Reported-$0.40
Revenue Reported105.548M
EPS Surprise 49.33%
Revenue Surprise 0.92%
NVRO Forecast & Estimates
19 analysts have analysed NVRO and the average price target is 8.87 USD. This implies a price increase of 51.87% is expected in the next year compared to the current price of 5.84.
For the next year, analysts expect an EPS growth of -29.92% and a revenue growth 0.32% for NVRO
Analysts
Analysts53.68
Price Target8.87 (51.88%)
EPS Next Y-29.92%
Revenue Next Year0.32%
NVRO Financial Highlights
Over the last trailing twelve months NVRO reported a non-GAAP Earnings per Share(EPS) of -1.92. The EPS increased by 25.29% compared to the year before.
Income Statements
Revenue(TTM)408.52M
Net Income(TTM)-113.44M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.48% | ||
| ROE | -49.11% | ||
| Debt/Equity | 0.98 |
Chartmill High Growth Momentum
EPS Q2Q%-60%
Sales Q2Q%-9.15%
EPS 1Y (TTM)25.29%
Revenue 1Y (TTM)-3.92%
NVRO Ownership
Ownership
Inst Owners99.47%
Shares37.88M
Float37.30M
Ins Owners2.02%
Short Float %N/A
Short RatioN/A
NVRO Industry Overview
NVRO operates in the Health Care Equipment sub-industry within the Health Care sector. This group contains 127 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
62/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
11%
Outperformed 11% of sub-industries
6 Month Rank
11%
Outperformed 11% of sub-industries
Industry Fundamentals & Breadth
- Members
- 127
- New Highs
- 3.9%
- New Lows
- 10.2%
- Average ROE
- 17.2%
- Average Profit Margin
- 20.2%
- Average Operating Margin
- 22.4%
- Average P/E
- 28.9
- Average Fwd P/E
- 24.6
- Average Debt/Equity
- 0.5
NVRO Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 40.01 | 165.737B | ||
| ABT | ABBOTT LABORATORIES | 14.94 | 163.098B | ||
| SYK | STRYKER CORP | 21.26 | 123.101B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.81 | 86.867B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.39 | 47.438B | ||
| IDXX | IDEXX LABORATORIES INC | 38.38 | 45.134B | ||
| BDX | BECTON DICKINSON AND CO | 10.95 | 42.574B | ||
| RMD | RESMED INC | 17.69 | 31.633B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.26 | 31.256B | ||
| DXCM | DEXCOM INC | 23.33 | 22.83B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.76 | 16.028B | ||
| PEN | PENUMBRA INC | 63.95 | 12.818B | ||
| PODD | INSULET CORP | 28.2 | 12.666B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVRO
Company Profile
Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,099 full-time employees. The company went IPO on 2014-11-06. The firm is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. The company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Company Info
IPO: 2014-11-06
NEVRO CORP
1800 Bridge Parkway
Redwood City CALIFORNIA 94065 US
CEO: D. Keith Grossman
Employees: 1099
Phone: 16502510005
NEVRO CORP / NVRO FAQ
What does NVRO do?
Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,099 full-time employees. The company went IPO on 2014-11-06. The firm is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. The company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
What is the current price of NVRO stock?
The current stock price of NVRO is 5.84 USD.
What is the dividend status of NEVRO CORP?
NVRO does not pay a dividend.
What is the ChartMill technical and fundamental rating of NVRO stock?
NVRO has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists NVRO stock?
NVRO stock is listed on the New York Stock Exchange exchange.
What is NEVRO CORP worth?
NEVRO CORP (NVRO) has a market capitalization of 221.22M USD. This makes NVRO a Micro Cap stock.
What is the next earnings date for NVRO stock?
NEVRO CORP (NVRO) will report earnings on 2025-05-05, after the market close.